SRPX2 and central nervous system cancer: Given that gliomas invade mainly along two routes, the white matter tracts and the blood vessels (Giese and Westphal, 1996), it could be speculated that SRPX2 may play a role in the latter and not the former in the subset of glioblastoma with hypomethylation bias/astrocytic signature enrichment.